Skip to main content
Top
Published in: Journal of Neural Transmission 4/2021

01-04-2021 | Dystonia | Neurology and Preclinical Neurological Studies - Review Article

Dystonia and leveraging oral pharmacotherapy

Authors: Michelle Ann C. Sy, Hubert H. Fernandez

Published in: Journal of Neural Transmission | Issue 4/2021

Login to get access

Abstract

Dystonia is a clinically diverse disorder, characterized by sustained or intermittent muscle contractions causing abnormal and often repetitive movements and/or postures. Accurate clinical diagnosis is tantamount to effective dystonia management. Current guidelines in the treatments of dystonia, including oral therapy, are prescribed to improve symptoms and to restore functional capacity. Identifying treatable causes from co-existing phenomenologies is relevant to provide the most optimal and disease-specific medications. In other forms of dystonia, genetic factors may affect outcome. Moreover, proper selection of patients, early initiation of medications and customized drug titration are keys to increasing the chances of success when using oral therapies for dystonia. Treatment of dystonia primarily involves agents that target dopamine and acetylcholine receptors. Other drugs used include benzodiazepines, baclofen, antiepileptics, some antipsychotics drugs and antihistamine, with different levels of evidence of effectiveness. Unfortunately, most of the widely used drugs have low levels of evidence and are primarily based on anecdotal experiences. Finally, other adjunctive therapeutic strategies are often necessary to complement oral therapy.
Literature
go back to reference Adler A, Peselow E, Rotrosen J, Duncan E, Angrist B (1993) Brief reports vitamin. Biol Psychiatry 9:1405–1407 Adler A, Peselow E, Rotrosen J, Duncan E, Angrist B (1993) Brief reports vitamin. Biol Psychiatry 9:1405–1407
go back to reference Adler LA, Edson R, Lavori P, Peselow E, Duncan E, Rosenthal M et al (1998) Long-term treatment effects of vitamin e for tardive dyskinesia. Biol Psychiatry 19:134–138 Adler LA, Edson R, Lavori P, Peselow E, Duncan E, Rosenthal M et al (1998) Long-term treatment effects of vitamin e for tardive dyskinesia. Biol Psychiatry 19:134–138
go back to reference Albanese MA, Barnes MP, Bhatia KP, Fernandez-alvarez E (2006) A systematic review on the diagnosis and treatment of primary (idiopathic) dystonia and dystonia plus syndromes: report of an EFNS/MDS-ES Task Force. Eur J Neurol 26:433–444CrossRef Albanese MA, Barnes MP, Bhatia KP, Fernandez-alvarez E (2006) A systematic review on the diagnosis and treatment of primary (idiopathic) dystonia and dystonia plus syndromes: report of an EFNS/MDS-ES Task Force. Eur J Neurol 26:433–444CrossRef
go back to reference Albanese A, Asmus F, Bhatia KP, Elia AE, Elibol B, Filippini G et al (2009) EFNS guidelines on diagnosis and treatment of primary dystonias. Eur J Neurol 1:5–18 Albanese A, Asmus F, Bhatia KP, Elia AE, Elibol B, Filippini G et al (2009) EFNS guidelines on diagnosis and treatment of primary dystonias. Eur J Neurol 1:5–18
go back to reference Albanese A, Di Giovanni M, Lalli S (2019) Dystonia: diagnosis and management. Eur J Neurol 26(1):5–17PubMedCrossRef Albanese A, Di Giovanni M, Lalli S (2019) Dystonia: diagnosis and management. Eur J Neurol 26(1):5–17PubMedCrossRef
go back to reference Anca MH, Zaccai TF, Badarna S, Lozano AM, Lang AE, Giladi N (2003) Natural history of oppenheim ’ s dystonia (DYT1) in Israel. J Child Neurol 18(5):325–330PubMedCrossRef Anca MH, Zaccai TF, Badarna S, Lozano AM, Lang AE, Giladi N (2003) Natural history of oppenheim ’ s dystonia (DYT1) in Israel. J Child Neurol 18(5):325–330PubMedCrossRef
go back to reference Anderson KE, Stamler D, Davis MD, Factor SA, Hauser RA, Isojärvi J et al (2017) Deutetrabenazine for treatment of involuntary movements in patients with tardive dyskinesia ( AIM-TD ): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Psyc 366(17):1–10 Anderson KE, Stamler D, Davis MD, Factor SA, Hauser RA, Isojärvi J et al (2017) Deutetrabenazine for treatment of involuntary movements in patients with tardive dyskinesia ( AIM-TD ): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Psyc 366(17):1–10
go back to reference Ankenman R, Salvatore MF (2007) Low dose alpha-methyl-para-tyrosine (AMPT) in the treatment of dystonia and dyskinesia. J NeuropsycClinNeurosci 19(1):65–69 Ankenman R, Salvatore MF (2007) Low dose alpha-methyl-para-tyrosine (AMPT) in the treatment of dystonia and dyskinesia. J NeuropsycClinNeurosci 19(1):65–69
go back to reference Ann J, Torres KL, Rosales RL (2017) Nonmotor symptoms in dystonia. Internat Rev Neurobiol 134:1335–1371CrossRef Ann J, Torres KL, Rosales RL (2017) Nonmotor symptoms in dystonia. Internat Rev Neurobiol 134:1335–1371CrossRef
go back to reference Badillo SPJ, Jamora RDG (2019) Zolpidem for the treatment of dystonia. Front Neurol 10:1–7CrossRef Badillo SPJ, Jamora RDG (2019) Zolpidem for the treatment of dystonia. Front Neurol 10:1–7CrossRef
go back to reference Batla A (2012) Neurology DM. Treat Focal Dystonia 2:213–229 Batla A (2012) Neurology DM. Treat Focal Dystonia 2:213–229
go back to reference Brien CFO, Jimenez R, Hauser RA, Factor SA, Burke J, Mandri D et al (2015) NBI-98854, a selective monoamine transport inhibitor for the treatment of tardive dyskinesia : a randomized, double-blind, placebo-controlled study. Move Dis 30(12):1681–1687CrossRef Brien CFO, Jimenez R, Hauser RA, Factor SA, Burke J, Mandri D et al (2015) NBI-98854, a selective monoamine transport inhibitor for the treatment of tardive dyskinesia : a randomized, double-blind, placebo-controlled study. Move Dis 30(12):1681–1687CrossRef
go back to reference Burke RE, Fahn S, Marsden CD (1986) Torsion dystonia: a double-blind, prospective trial of high-dosage trihexyphenidyl. Neurology 36(2):160–164PubMedCrossRef Burke RE, Fahn S, Marsden CD (1986) Torsion dystonia: a double-blind, prospective trial of high-dosage trihexyphenidyl. Neurology 36(2):160–164PubMedCrossRef
go back to reference Cai C, Shi W, Zeng Z, Zhang M, Ling C, Chen L et al (2013) GTP cyclohydrolase I and tyrosine hydroxylase gene mutations in familial and sporadic dopa-responsive dystonia patients. PLoS ONE 8(6):4–8CrossRef Cai C, Shi W, Zeng Z, Zhang M, Ling C, Chen L et al (2013) GTP cyclohydrolase I and tyrosine hydroxylase gene mutations in familial and sporadic dopa-responsive dystonia patients. PLoS ONE 8(6):4–8CrossRef
go back to reference De Silva R, Greenfield J, Cook A, Bonney H, Vallortigara J, Hunt B et al (2019) Guidelines on the diagnosis and management of the progressive ataxias. Orphanet J Rare Dis 14(1):1–10CrossRef De Silva R, Greenfield J, Cook A, Bonney H, Vallortigara J, Hunt B et al (2019) Guidelines on the diagnosis and management of the progressive ataxias. Orphanet J Rare Dis 14(1):1–10CrossRef
go back to reference Decker BL, Davis J, Janowsky DS, El Yousef K, Sekerke HJ (1971) Amantadine hydrochloride treatment of tardive dyskinesia. N Engl J Med 285:860PubMedCrossRef Decker BL, Davis J, Janowsky DS, El Yousef K, Sekerke HJ (1971) Amantadine hydrochloride treatment of tardive dyskinesia. N Engl J Med 285:860PubMedCrossRef
go back to reference Delnooz CCS, Van De WBPC (2012) Current and future medical treatment in primary dystonia. TheraAdvNeurol Dis 12:221–240 Delnooz CCS, Van De WBPC (2012) Current and future medical treatment in primary dystonia. TheraAdvNeurol Dis 12:221–240
go back to reference Dufresne RL, Becker RE, Mastrati P (1978) Diazepam in tardive dyskinesia. Move Dis 17:523–527 Dufresne RL, Becker RE, Mastrati P (1978) Diazepam in tardive dyskinesia. Move Dis 17:523–527
go back to reference Fahn S (1987) Systemic therapy of dystonia. Can J NeurolSci 14(3):528–532CrossRef Fahn S (1987) Systemic therapy of dystonia. Can J NeurolSci 14(3):528–532CrossRef
go back to reference Fernandez HH, Friedman JH (1999) The role of atypical antipsychotics in the treatment of movement disorders. Move Dis Soc 11(6):467–483 Fernandez HH, Friedman JH (1999) The role of atypical antipsychotics in the treatment of movement disorders. Move Dis Soc 11(6):467–483
go back to reference Fernandez HH, Meltzer HY, Woods SW, Bega D, Ledoux MS, Davis C et al (2017) Randomized controlled trial of deutetrabenazine for tardive dyskinesia The ARM-TD study. Neurology 7:2003–2010CrossRef Fernandez HH, Meltzer HY, Woods SW, Bega D, Ledoux MS, Davis C et al (2017) Randomized controlled trial of deutetrabenazine for tardive dyskinesia The ARM-TD study. Neurology 7:2003–2010CrossRef
go back to reference Friedman J, Roze E, Abdenur JE, Chang R, Gasperini S, Saletti V et al (2012) Sepiapterin reductase deficiency : a treatable mimic of cerebral palsy. Ann Neurol 123:520–530CrossRef Friedman J, Roze E, Abdenur JE, Chang R, Gasperini S, Saletti V et al (2012) Sepiapterin reductase deficiency : a treatable mimic of cerebral palsy. Ann Neurol 123:520–530CrossRef
go back to reference Frucht SJ (2017) Dystonic storm : a practical clinical and video review. Move Dis 2:1–8 Frucht SJ (2017) Dystonic storm : a practical clinical and video review. Move Dis 2:1–8
go back to reference Gilbert GJ, Petersburg S (2015) The medical treatment of spasmodic torticollis. Eur J Neurol 15:7–10 Gilbert GJ, Petersburg S (2015) The medical treatment of spasmodic torticollis. Eur J Neurol 15:7–10
go back to reference Glazer WM, Moore DC, Bowers MB, Bunney BS, Roffman M (1985) The treatment of tardive dyskinesia with baclofen. Psychopharmacology 87(4):480–483PubMedCrossRef Glazer WM, Moore DC, Bowers MB, Bunney BS, Roffman M (1985) The treatment of tardive dyskinesia with baclofen. Psychopharmacology 87(4):480–483PubMedCrossRef
go back to reference Gn S (2017) Case report management of oromandibulardystonia : a case report and literature update. Movement 17:109–234 Gn S (2017) Case report management of oromandibulardystonia : a case report and literature update. Movement 17:109–234
go back to reference Greene P (1992) Baclofen in the treatment of dystonia. ClinNeuropharmacol 15(4):276–288 Greene P (1992) Baclofen in the treatment of dystonia. ClinNeuropharmacol 15(4):276–288
go back to reference Greene P, Shale H, Fahn S (1988) Analysis of open-label trials in torsion dystonia using high dosages of anticholinergics and other drugs. J Move Dis Soc 3(1):46–60CrossRef Greene P, Shale H, Fahn S (1988) Analysis of open-label trials in torsion dystonia using high dosages of anticholinergics and other drugs. J Move Dis Soc 3(1):46–60CrossRef
go back to reference Hauser RA, Factor SA, Marder SR, Knesevich MA (2017) KINECT 3: a phase 3 randomized, double-blind, placebo-controlled trial of valbenazine for tardive dyskinesia. Am J Psyc 2:10–34 Hauser RA, Factor SA, Marder SR, Knesevich MA (2017) KINECT 3: a phase 3 randomized, double-blind, placebo-controlled trial of valbenazine for tardive dyskinesia. Am J Psyc 2:10–34
go back to reference Jankovic J (1981) I reatment of hyperkmeac movement disorders with tetrabenazine : a double-blind crossover study. Ann Neurol 1:41–47 Jankovic J (1981) I reatment of hyperkmeac movement disorders with tetrabenazine : a double-blind crossover study. Ann Neurol 1:41–47
go back to reference Jinnah HA (2019) TheDystonias. Contin Lifelong Learn Neurol 25(4):976–1000CrossRef Jinnah HA (2019) TheDystonias. Contin Lifelong Learn Neurol 25(4):976–1000CrossRef
go back to reference Josiassen BRC, Kane JM, Liang GS, Burke J, Brien CFO (2007) Long-term safety and tolerability of valbenazine (NBI-98854) in subjects with tardive dyskinesia and a diagnosis of schizophrenia. Mood Dis 47(3):8 Josiassen BRC, Kane JM, Liang GS, Burke J, Brien CFO (2007) Long-term safety and tolerability of valbenazine (NBI-98854) in subjects with tardive dyskinesia and a diagnosis of schizophrenia. Mood Dis 47(3):8
go back to reference Karp BI, Goldstein SR, Chen R, Samii A, Bara-jimenez W, Hallett M (1999) An open trial of clozapine for dystonia. Move Dis Soc 14(4):652–657CrossRef Karp BI, Goldstein SR, Chen R, Samii A, Bara-jimenez W, Hallett M (1999) An open trial of clozapine for dystonia. Move Dis Soc 14(4):652–657CrossRef
go back to reference Kiriakakis V, Bhatia KP, Quinn NP, Marsden CD (1998) The natural history of tardive dystonia A long-term follow-up study of 107 cases. Brain J Neurol 1998:2053–2066CrossRef Kiriakakis V, Bhatia KP, Quinn NP, Marsden CD (1998) The natural history of tardive dystonia A long-term follow-up study of 107 cases. Brain J Neurol 1998:2053–2066CrossRef
go back to reference Lizarraga KJ, Al-shorafat D, Fox S (2019) Update on current and emerging therapies for dystonia. Neurodegen dis manag 9:135–147CrossRef Lizarraga KJ, Al-shorafat D, Fox S (2019) Update on current and emerging therapies for dystonia. Neurodegen dis manag 9:135–147CrossRef
go back to reference Lubarr N, Bressman S (2011) Treatment of generalized dystonia. Move Dis 26(6):274–289 Lubarr N, Bressman S (2011) Treatment of generalized dystonia. Move Dis 26(6):274–289
go back to reference Ma RAH, Unit G (2004) Case report Pyruvate dehydrogenase deficiency presenting as dystonia in childhood. Develop Med Child Neurol 4:710–712 Ma RAH, Unit G (2004) Case report Pyruvate dehydrogenase deficiency presenting as dystonia in childhood. Develop Med Child Neurol 4:710–712
go back to reference Mariotti P, Fasano A, Contarino MF, Della MG, Piastra M, Genovese O et al (2007) Management of status dystonicus: our experience and review of the literature. Move Dis 22(7):963–968CrossRef Mariotti P, Fasano A, Contarino MF, Della MG, Piastra M, Genovese O et al (2007) Management of status dystonicus: our experience and review of the literature. Move Dis 22(7):963–968CrossRef
go back to reference Mentzel CL, Bakker PR, van Os J, Drukker M, Matroos GE, Hoek HW, Tijssen MA, van Harten PN (2017) Effect of antipsychotic type and dose changes on tardive dyskinesia and parkinsonism severity in patients with a serious mental illness: the curaçao extrapyramidal syndromes study XII. J Clin Psychiatry 78(3):e279–e285PubMedCrossRef Mentzel CL, Bakker PR, van Os J, Drukker M, Matroos GE, Hoek HW, Tijssen MA, van Harten PN (2017) Effect of antipsychotic type and dose changes on tardive dyskinesia and parkinsonism severity in patients with a serious mental illness: the curaçao extrapyramidal syndromes study XII. J Clin Psychiatry 78(3):e279–e285PubMedCrossRef
go back to reference Miyazaki Y, Sako W, Asanuma K, Izumi Y, Miki T, Kaji R (2012) Efficacy of zolpidem for dystonia : a study among different subtypes. Front Neurol 3:1–58 Miyazaki Y, Sako W, Asanuma K, Izumi Y, Miki T, Kaji R (2012) Efficacy of zolpidem for dystonia : a study among different subtypes. Front Neurol 3:1–58
go back to reference Miyazaki Y, Koizumi H, Miyamoto R, Kawarai T, Kaji R (2015) Treatment of isolated dystonia with zolpidem. Move Dis ClinPract 8:309–311 Miyazaki Y, Koizumi H, Miyamoto R, Kawarai T, Kaji R (2015) Treatment of isolated dystonia with zolpidem. Move Dis ClinPract 8:309–311
go back to reference Papapetropoulos S, Singer C (2006) Improvement of cervico-trunco-brachial segmental dystonia with topiramate. J Neurol 253(4):535–536PubMedCrossRef Papapetropoulos S, Singer C (2006) Improvement of cervico-trunco-brachial segmental dystonia with topiramate. J Neurol 253(4):535–536PubMedCrossRef
go back to reference Pappa S, Tsouli S, Apostolou G, Mavreas V, Konitsiotis S (2010) Effects of amantadine on tardive dyskinesia: a randomized, double-blind, placebo-controlled study. ClinNeuropharmacol 33(6):271–275 Pappa S, Tsouli S, Apostolou G, Mavreas V, Konitsiotis S (2010) Effects of amantadine on tardive dyskinesia: a randomized, double-blind, placebo-controlled study. ClinNeuropharmacol 33(6):271–275
go back to reference Rice J, Waugh Mary-Clare MC (2009) Pilot study on trihexyphenidyl in the treatment of dystonia in children with cerebral palsy. J Child Neurol 24(2):176–182PubMedCrossRef Rice J, Waugh Mary-Clare MC (2009) Pilot study on trihexyphenidyl in the treatment of dystonia in children with cerebral palsy. J Child Neurol 24(2):176–182PubMedCrossRef
go back to reference Sanger TD, Bastian A, Brunstrom J, Damiano D, Delgado M, Dure L et al (2007) Prospective open-label clinical trial of trihexyphenidyl in children with secondary dystonia due to cerebral palsy. J Child Neurol 22(5):530–537PubMedCrossRef Sanger TD, Bastian A, Brunstrom J, Damiano D, Delgado M, Dure L et al (2007) Prospective open-label clinical trial of trihexyphenidyl in children with secondary dystonia due to cerebral palsy. J Child Neurol 22(5):530–537PubMedCrossRef
go back to reference Schiller A, Wevers RA, Steenbergen GCH, Blau N, Jung HH (2004) Long-term course of L-dopa-responsive dystonia caused by tyrosine hydroxylase deficiency. Neurology 4:1524–1527CrossRef Schiller A, Wevers RA, Steenbergen GCH, Blau N, Jung HH (2004) Long-term course of L-dopa-responsive dystonia caused by tyrosine hydroxylase deficiency. Neurology 4:1524–1527CrossRef
go back to reference Simpson GM, Lee JH, Shrivastava RK (1978) Clozapine in tardive dyskinesia. Psychopharmacology 56(1):75–80PubMedCrossRef Simpson GM, Lee JH, Shrivastava RK (1978) Clozapine in tardive dyskinesia. Psychopharmacology 56(1):75–80PubMedCrossRef
go back to reference Snoek JW, Zwarts MJ, Van WTW, Van HJJ, Der KV, Speelman JD (1996) Botulinurn toxin versus trihexyphenidyl in cervical dystonia. Neurology 6:19 Snoek JW, Zwarts MJ, Van WTW, Van HJJ, Der KV, Speelman JD (1996) Botulinurn toxin versus trihexyphenidyl in cervical dystonia. Neurology 6:19
go back to reference Sullivan KL, Hauser RA, Louis ED, Chari G, Zesiewicz TA (2005) Levetiracetam for the treatment of generalized dystonia. Park Related Disord 11:469–471CrossRef Sullivan KL, Hauser RA, Louis ED, Chari G, Zesiewicz TA (2005) Levetiracetam for the treatment of generalized dystonia. Park Related Disord 11:469–471CrossRef
go back to reference Termsarasab P, Thammongkolchai T, Frucht SJ (2016) Medical treatment of dystonia. J Clin Mov Disord [Internet]. 3(1):19. Available from: http://clinicalmovementdisorders.biomedcentral.com/articles/https://doi.org/10.1186/s40734-016-0047-6 Termsarasab P, Thammongkolchai T, Frucht SJ (2016) Medical treatment of dystonia. J Clin Mov Disord [Internet]. 3(1):19. Available from: http://​clinicalmovement​disorders.​biomedcentral.​com/​articles/​https://​doi.​org/​10.​1186/​s40734-016-0047-6
go back to reference Thaker GK, Nguyen JA, Strauss ME, Jacobson R, Kaup BA, Tamminga CA (1990) Clonazepam treatment of tardive dyskinesia: a practical GABAmimetic strategy. Am J Psychiatry 147(4):445–451PubMedCrossRef Thaker GK, Nguyen JA, Strauss ME, Jacobson R, Kaup BA, Tamminga CA (1990) Clonazepam treatment of tardive dyskinesia: a practical GABAmimetic strategy. Am J Psychiatry 147(4):445–451PubMedCrossRef
go back to reference Trosch RM, Friedman JH, Lannon C, Smith D, Seeberger LC, Brien CFO et al (1998) Clozapine use in parkinson’s disease : a retrospective analysis of a large multicentered clinical experience. Move Dis 13(3):377–382CrossRef Trosch RM, Friedman JH, Lannon C, Smith D, Seeberger LC, Brien CFO et al (1998) Clozapine use in parkinson’s disease : a retrospective analysis of a large multicentered clinical experience. Move Dis 13(3):377–382CrossRef
go back to reference Vanasse M, Chouinard S (2010) A case of secondary dystonia responding to levodopa. J Child Neurol 25(6):780–781PubMedCrossRef Vanasse M, Chouinard S (2010) A case of secondary dystonia responding to levodopa. J Child Neurol 25(6):780–781PubMedCrossRef
go back to reference Victorri-vigneau C, Dailly E, Veyrac G, Jolliet P (2007) Evidence of zolpidem abuse and dependence : results of the french centre for evaluation and information on pharmacodependence (CEIP) network survey. Br J ClinPharmacol 64(2):198–209 Victorri-vigneau C, Dailly E, Veyrac G, Jolliet P (2007) Evidence of zolpidem abuse and dependence : results of the french centre for evaluation and information on pharmacodependence (CEIP) network survey. Br J ClinPharmacol 64(2):198–209
go back to reference Zesiewicz TA, Louis ED (2004) Substantial improvement in a meige’s syndrome patient with levetiracetam treatment. Movement Dis 19(12):2002–2005CrossRef Zesiewicz TA, Louis ED (2004) Substantial improvement in a meige’s syndrome patient with levetiracetam treatment. Movement Dis 19(12):2002–2005CrossRef
go back to reference Zheng W, Xiang YQ, Ng CH, Ungvari GS, Chiu HF, Xiang YT (2016) Extract of ginkgo biloba for tardive dyskinesia: meta-analysis of randomized controlled trials. Pharmacopsychiatry 49(3):107–111PubMedCrossRef Zheng W, Xiang YQ, Ng CH, Ungvari GS, Chiu HF, Xiang YT (2016) Extract of ginkgo biloba for tardive dyskinesia: meta-analysis of randomized controlled trials. Pharmacopsychiatry 49(3):107–111PubMedCrossRef
Metadata
Title
Dystonia and leveraging oral pharmacotherapy
Authors
Michelle Ann C. Sy
Hubert H. Fernandez
Publication date
01-04-2021
Publisher
Springer Vienna
Keywords
Dystonia
Levodopa
Published in
Journal of Neural Transmission / Issue 4/2021
Print ISSN: 0300-9564
Electronic ISSN: 1435-1463
DOI
https://doi.org/10.1007/s00702-021-02339-7

Other articles of this Issue 4/2021

Journal of Neural Transmission 4/2021 Go to the issue

Neurology and Preclinical Neurological Studies - Review Article

Arching deep brain stimulation in dystonia types

Neurology and Preclinical Neurological Studies - Review Article

Combined dystonias: clinical and genetic updates

Neurology and Preclinical Neurological Studies - Review Article

X-linked dystonia Parkinsonism: crossing a new threshold

Neurology and Preclinical Neurological Studies - Review Article

Neurorehabilitation in dystonia: a holistic perspective

Neurology and Preclinical Neurological Studies - Review Article

Contemporary clinical neurophysiology applications in dystonia

Neurology and Preclinical Neurological Studies - Review Article

New modalities and directions for dystonia care